The risks of neonatal convulsions and neonatal withdrawal syndrome seem to increase when a pregnant women uses selective serotonin reuptake inhibitors (SSRIs), with paroxetine being the worst offender, according to cases reported by 72 countries to the World Health Organization's Collaborating Centre for International Drug Monitoring in Uppsala, Sweden.
The risks of neonatal convulsions and neonatal withdrawal syndrome seem to increase when a pregnant women uses selective serotonin reuptake inhibitors (SSRIs), with paroxetine being the worst offender, according to cases reported by 72 countries to the World Health Organization's Collaborating Centre for International Drug Monitoring in Uppsala, Sweden.
Of 93 suspected cases of SSRI-induced neonatal withdrawal syndrome (including 13 cases of seizures) reported by November 2003, 64 were associated with paroxetine, 14 with fluoxetine, nine with sertraline, and seven with citalopram.
As a result, the investigators recommend that paroxetine not be used during pregnancy or, if it must be used, that it be given at the lowest effective dose. They also recommend that the use of other SSRIs during pregnancy be carefully monitored, and that physicians report any new cases of neonatal withdrawal syndrome promptly to appropriate authorities.
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More